Protein Kinase Inhibitors

Kinase Inhibitor

Carcinoma, Renal Cell

<section class="Section" data-sectioncode="34089-3"><a name="s11"></a><a name="section-10"></a><h1>11 DESCRIPTION</h1>CABOMETYX is the (S)-malate salt of cabozantinib, a kinase inhibitor. Cabozantinib (S)-malate is described chemically as N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate. The molecular formula is C28H24FN3O5•C4H6O5 and the molecular weight is 635.6 Daltons as malate salt. The chemical structure of cabozantinib (S)-malate salt is:<div class="Figure"><a name="m1"></a><img alt="image of chemical structure of CABOMETYX" src="cabometyx-chem-struct.jpg"/></div>Cabozantinib (S)-malate salt is a white to off-white solid that is practically insoluble in aqueousmedia.CABOMETYX (cabozantinib) tablets for oral use are supplied as film-coated tablets containing 20 mg, 40 mg, or 60 mg of cabozantinib, which is equivalent to 25 mg, 51 mg, or 76 mg of cabozantinib (S)-malate, respectively. CABOMETYX also contains the following inactive ingredients: microcrystalline cellulose, lactose anhydrous, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate.The film coating contains hypromellose, titanium dioxide, triacetin, and iron oxide yellow.</section>

CABOMETYX

cabozantinib

cabozantinib 20 MG Oral Tablet

Cabometyx

cabozantinib 20 MG Oral Tablet [Cabometyx]

cabozantinib 40 MG Oral Tablet

cabozantinib 40 MG Oral Tablet [Cabometyx]

cabozantinib 60 MG Oral Tablet

cabozantinib 60 MG Oral Tablet [Cabometyx]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Submit MSL Request 

Coverage Authorization Request 

Coverage Authorization Appeals 

EASE Enrollment Patient Authorization (Form 2/2) - Online 

Enroll in Patient Savings Program 

Instructions For Use: Advanced Renal Cell Carcinoma (RCC)

Instructions For Use: Hepatocellular Carcinoma (HCC)

Instructions For Use: Differentiated Thyroid Cancer (DTC)